Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates

Kaabi, Nawal Al; Oulhaj, Abderrahim; Ganesan, Subhashini; Hosani, Farida Ismail Al; Najim, Omer; Ibrahim, Halah; Acuña, Juan; Alsuwaidi, Ahmed R.; Kamour, Ashraf; Alzaabi, Ashraf; Shehhi, Badreyya Ahmed Al; Alsafar, Habiba; Hussein, Salah; Abdalla, Jehad; Mansoori, Dalal Saeed Naser Al; Hammadi, Ahmed Abdul Kareem Al; Amari, Mohammed A.; Romaithi, Ahmed Khamis Al; Weber, Stefan; Elavalli, Santosh; Eltantawy, Islam; Alghaithi, Noura Khamis; Azazi, Jumana Nafiz Al; Holt, Stephen Geoffrey; Mostafa, Mohamed; Halwani, Rabih; Khalak, Hanif; Elamin, Wael; Zaher, Walid

doi:10.1038/s41467-022-30835-1

Cited by 26 publications

(27 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study indicates that two doses of Pfizer-BioNTech or Sinopharm vaccines at least fourteen days after administration provided significant reduction in coronavirus-associated hospitalizations at Prince Hamza Hospital in Jordan. Based upon the hospitalization rates of patients in our patient cohort, it is evident that Sinopharm (VE 92%) is less effective than Pfizer-BioNTech (VE 67%) These results are consistent with previous studies, in particular, those done during the period between March and July, and February and August 2021, which showed the VE of Pfizer-BioNTech and Sinopharm against hospitalization rates to be 86% (95% CI = 82–88%) ( 10 , 11 ), and 79.6% (95% CI 77.7–81.3%) ( 12 ).…”

Section: Discussionsupporting

confidence: 91%

Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan

Al-Momani

Aldajah

Alda'ajah

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThere is a need to establish the effectiveness of the coronavirus disease 2019 (COVID-19) vaccines in reducing COVID-19-related hopitalization of patients in Jordan. As the vaccination program accelerates, it is important to determine whether the vaccines' effectiveness (VE) has successfully reduced the number of acute cases admitted to hospital.MethodsTo determine the efficacy of Pfizer-BioNTech and Sinopharm COVID-19 vaccines among Jordanian patients admitted to Prince Hamza hospital, a single center case-control study was performed. The study analyzed the hospitalization rates of vaccinated (n = 536) and unvaccinated (n = 585) individuals across the 2-month period from February 6 to April 6, 2022. The cases were patients who tested positive for SARS-CoV-2 (“case-patients”), whilst the control group were hospital patients who did not test positive for SARS-CoV-2 (“control-patients”).ResultsThis study found that among 1,121 total participants (561 cases and 560 control), the overall vaccine effectiveness (VE) among the participants was 84% (95% Cl 79–88%). VE was higher in females (88%, 95% Cl 84–93%) than in males (77%, 95% Cl 67–84%) (p < 0.001), and it was highest in those between the ages of 18 and 28-years-old (95%, 95% CI 86–98%). For patients with pre-existing conditions, including chronic heart disease, chronic lung disease, and diabetes, VE was higher compared to patients with no comorbidities, though the difference was not statistically significant. Finally, in comparing all vaccinated participants, VE was higher for those who received the Pfizer vaccine (VE = 92%, 95% CI 88–94%) (OR 0.08, 95% CI 0.06–0.12) than for those who received the Sinopharm vaccine (VE = 67%, 95% CI 52–78%) (OR 0.33, 95% CI 0.22–0.48); (p = 0.011).ConclusionOverall, Pfizer and Sinopharm vaccines were found to be effective in limiting hospitalizations for acute cases of coronavirus among Jordanian adult's patient's cohort between February 6 and April 6, 2022, especially among patients with comorbidities.

show abstract

Section: Discussionsupporting

confidence: 91%

Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan

Al-Momani

Aldajah

Alda'ajah

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…Another point that merits mention is that our dataset was retrieved from a private company’s database, rather than from a well-structured national registry for COVID-19 infection and vaccination. At the time the study was conducted, such a registry was unavailable in Lebanon, unlike the situation in other middle eastern countries such as Qatar and the United Arab Emirates [ 19 , 46 , 52 ]. The studied cohort included mostly young and healthy individuals, which is not representative of the Lebanese population regarding age, comorbidities, and socioeconomic status.…”

Section: Discussionmentioning

confidence: 99%

Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants

et al. 2022

View full text Add to dashboard Cite

In this study involving a cohort of employees of the National Airline company in Lebanon, we assessed humoral immunity levels and the effectiveness of two COVID-19 vaccines, Gam-COVID-Vac versus BNT162b2, after two doses and after a homologous and heterologous BNT162b2 booster, in addition to the impact of hybrid immunity. Vaccine effectiveness (VE) was retrospectively determined against laboratory-confirmed SARS-CoV-2 infection during the periods of Delta and Omicron variants’ predominance, separately, and was calculated based on a case–control study design. The humoral immune response, measured by a SARS-CoV-2 anti-spike receptor-binding domain (RBD) IgG titer, was prospectively assessed after the aforementioned vaccination schemes at different time points. This study showed higher effectiveness of BNT162b2 after two doses (81%) compared to two doses of Gam-COVID-Vac (41.8%) against the Delta variant of SARS-CoV-2, which correlated with anti-spike antibody levels. Regarding the Omicron variant, protection against infection and antibody levels were severely compromised and the correlation between an anti-spike IgG titer and effectiveness was lost, unlike the situation during the Delta wave. Considering the booster vaccination schemes, a homologous BNT162b2 booster after a BNT162b2 primary vaccination induced a higher humoral immune response when compared to that induced by a heterologous BNT162b2 booster after a Gam-COVID-Vac primary vaccination. However, the VE of both booster regimens against the Omicron variant was almost equal (64% in the homologous regimen and 57% in heterologous regimen). Hybrid immunity evidenced a better humoral response and a greater and longer protection against Delta and Omicron infections compared to vaccination-induced immunity in COVID-19-naïve individuals. Finally, the findings show that VE waned with time during the same wave, highlighting the importance of reinforcing primary and booster COVID-19 vaccination mainly at the beginning of each wave during the surge of a new variant of concern.

show abstract

“…The third COVID-19 vaccine to be compared in this paper is Sinopharm (BBIBP-CorV), an inactivated virus combined with an alum adjuvant made from virus particles and grown in culture and thus improving immunogenicity [ 18 ]. BBIBP-CorV was created by the Beijing Institute of Biological Products and has a 79% efficacy [ 116 ]. Since BBIBP-CorV uses a completely inactivated virus, it is predicted to trigger an immune response against all SARS-CoV-2 proteins: nucleocapsid (N), membranes (M), envelope (E) proteins, and spike proteins (S) [ 117 ].…”

Section: Methodsmentioning

confidence: 99%

An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines

Al-Sheboul

Brown²,

Shboul

et al. 2022

Vaccines

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19) pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus, which is defined by its positive-sense single-stranded RNA (ssRNA) structure. It is in the order Nidovirales, suborder Coronaviridae, genus Betacoronavirus, and sub-genus Sarbecovirus (lineage B), together with two bat-derived strains with a 96% genomic homology with other bat coronaviruses (BatCoVand RaTG13). Thus far, two Alphacoronavirus strains, HCoV-229E and HCoV-NL63, along with five Betacoronaviruses, HCoV-HKU1, HCoV-OC43, SARS-CoV, MERS-CoV, and SARS-CoV-2, have been recognized as human coronaviruses (HCoVs). SARS-CoV-2 has resulted in more than six million deaths worldwide since late 2019. The appearance of this novel virus is defined by its high and variable transmission rate (RT) and coexisting asymptomatic and symptomatic propagation within and across animal populations, which has a longer-lasting impact. Most current therapeutic methods aim to reduce the severity of COVID-19 hospitalization and virus symptoms, preventing the infection from progressing from acute to chronic in vulnerable populations. Now, pharmacological interventions including vaccines and others exist, with research ongoing. The only ethical approach to developing herd immunity is to develop and provide vaccines and therapeutics that can potentially improve on the innate and adaptive system responses at the same time. Therefore, several vaccines have been developed to provide acquired immunity to SARS-CoV-2 induced COVID-19-disease. The initial evaluations of the COVID-19 vaccines began in around 2020, followed by clinical trials carried out during the pandemic with ongoing population adverse effect monitoring by respective regulatory agencies. Therefore, durability and immunity provided by current vaccines requires further characterization with more extensive available data, as is presented in this paper. When utilized globally, these vaccines may create an unidentified pattern of antibody responses or memory B and T cell responses that need to be further researched, some of which can now be compared within laboratory and population studies here. Several COVID-19 vaccine immunogens have been presented in clinical trials to assess their safety and efficacy, inducing cellular antibody production through cellular B and T cell interactions that protect against infection. This response is defined by virus-specific antibodies (anti-N or anti-S antibodies), with B and T cell characterization undergoing extensive research. In this article, we review four types of contemporary COVID-19 vaccines, comparing their antibody profiles and cellular aspects involved in coronavirus immunology across several population studies.

show abstract

Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates

Cited by 26 publications

References 20 publications

Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan

Effectiveness of Pfizer/BioNTech and Sinopharm COVID-19 vaccines in reducing hospital admissions in prince Hamza hospital, Jordan

Immunogenicity and Effectiveness of Primary and Booster Vaccine Combination Strategies during Periods of SARS-CoV-2 Delta and Omicron Variants

An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines

Contact Info

Product

Resources

About